ZL
ZLD.AU Zelira Therapeutics Ltd
- Market cap
- AUD 6.57M
- P/E
- -
- P/B
- 0.32x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- 0.7/5
Ratios use the latest price and the fiscal year ending Jun 2025.
Is ZLD.AU undervalued?
Graham numberThe Graham number of Zelira Therapeutics Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Zelira Therapeutics Ltd fundamental analysis
4 of 21 checks passedROE 0/2
ROE cannot be calculated: equity is negative or not reported.
ROA 0/1
Return on assets (-278.9%) is below the industry median (-51.4%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 1/1
Earnings per share grew over the past 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 1/1
Last year's EPS growth (90.2%) is above the industry median (-5.3%).
Revenue Growth 0/2
Revenue shrank 92.5% a year over the past 3 years.
Short-term Liquidity 0/1
Current assets do not cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 0/2
Debt to equity cannot be calculated: debt is not reported or equity is negative.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Cash Runway 0/2
Cash covers 0.0 years of the current cash burn.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 1/1
Price to book (0.3x) is below the industry median (4.4x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Zelira Therapeutics Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Zelira Therapeutics Ltd
Zelira Therapeutics Limited, a biopharmaceutical company, engages in the research, development, and commercialization of cannabinoid-based medicines for the treatment of various medical conditions in Australia and the United States. It offers formulations under the HOPE brand in Australia, Washington, Pennsylvania, and Louisiana, as well as develops ZENIVOL, a cannabinoid drug for the treatment of chronic insomnia. The company also provides over the counter (OTC) products, i…
Full company profileZelira Therapeutics Ltd financial statements
Zelira Therapeutics Ltd annual financial statements (AUD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 2.73K | 168K | 561K | 859K | 663K | 663K | 1.54M | 301K | 95.0K | 656.00 |
| Gross Profit | 300K | 100K | 314K | 859K | -275K | -39.2K | -5.72M | -3.22M | 10.3K | -803K |
| Operating Income | -876K | -6.32M | -2.83M | -4.24M | -7.84M | -9.65M | -13.4M | -7.41M | -5.94M | -3.95M |
| EBITDA | -876K | -3.71M | 635K | -4.23M | -7.71M | -9.41M | -13.1M | -6.79M | -36.4M | -4.05M |
| Net Income | -899K | -6.16M | -1.73M | -2.90M | -7.02M | -8.55M | -11.9M | -5.57M | -36.6M | -3.63M |
| EPS | -1.39 | -2.18 | -0.40 | -0.67 | -1.45 | -1.29 | -1.49 | -0.55 | -3.22 | -0.32 |
| Balance Sheet | ||||||||||
| Total Assets | 87.5K | 7.97M | 6.31M | 3.52M | 35.8M | 39.4M | 37.7M | 33.9M | 5.18M | 1.30M |
| Total Liabilities | 290K | 70.6K | 99.4K | 407K | 1.24M | 1.54M | 2.01M | 2.18M | 9.36M | 5.59M |
| Shareholders' Equity | -203K | 7.90M | 6.21M | 3.11M | 34.5M | 37.8M | 35.2M | 31.8M | -4.51M | -4.46M |
| Cash & Short-term Investments | 55.7K | 7.87M | 5.69M | 3.07M | 1.70M | 4.97M | 2.75M | 146K | 586K | 5.66K |
| Total Debt | 1.00M | - | - | 632K | 632K | 551K | 501K | 438K | 5.95M | 2.14M |
| Cash Flow | ||||||||||
| Operating Cash Flow | -332K | -2.20M | -2.62M | -3.34M | -6.94M | -8.62M | -9.43M | -7.25M | -4.39M | -4.91M |
| Capital Expenditure | 7.09K | 7.09K | 28.2K | 28.2K | 16.0K | 4.00 | 4.00 | 0.00 | 0.00 | 4.00 |
| Free Cash Flow | -332K | -2.21M | -2.62M | -3.37M | -6.95M | -8.62M | -9.43M | -7.25M | -4.39M | -4.91M |
| Ratios | ||||||||||
| ROE | - | -78.0% | -27.8% | -93.2% | -20.3% | -22.6% | -33.9% | -17.5% | - | - |
| ROA | -1,026.8% | -77.3% | -27.4% | -82.4% | -19.6% | -21.7% | -31.7% | -16.4% | -705.5% | -278.9% |
| Net Profit Margin | -32,917.1% | -3,670.4% | -308.1% | -337.2% | -1,057.6% | -1,288.8% | -775.4% | -1,850.8% | -38,513.0% | -553,029.3% |
| Debt to Equity | - | - | - | 0.20x | 0.02x | 0.01x | 0.01x | 0.01x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Zelira Therapeutics Ltd dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | AUD 8.58M | 3.03 | - |
| 2016 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:175 on Apr 14, 2022.
Who owns Zelira Therapeutics Ltd
- Insiders 56.70%
- Institutions 0.00%
- Public & others 43.30%
- Shares outstanding 13.1M
- Free float 6.01M
Zelira Therapeutics Ltd company profile
- Company name
- Zelira Therapeutics Ltd
- Ticker
- ZLD.AU
- ISIN
- AU000000ZLD1
- Exchange
- Australian Securities Exchange
- Listed since
- Jul 28, 2003
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- June
- Address
- 101 St Georges Terrace, Perth, WA, Australia, 6000
- Phone
- 61 8 6558 0886
- Website
- zeliratx.com
About Zelira Therapeutics Ltd
Zelira Therapeutics Limited, a biopharmaceutical company, engages in the research, development, and commercialization of cannabinoid-based medicines for the treatment of various medical conditions in Australia and the United States. It offers formulations under the HOPE brand in Australia, Washington, Pennsylvania, and Louisiana, as well as develops ZENIVOL, a cannabinoid drug for the treatment of chronic insomnia. The company also provides over the counter (OTC) products, including SprinJeneCBD, an oral care product; and acne treatment products under the RAF FIVE name, as well as Zyraydi, an enhanced distillate capture and dissolution matrix technology. In addition, it offers products for autism and chronic noncancer pain. The company was formerly known as Zelda Therapeutics Limited and changed its name to Zelira Therapeutics Limited in December 2019. Zelira Therapeutics Limited was incorporated in 2003 and is based in Perth, Australia.
Zelira Therapeutics Ltd management
6- Mr. Osagie O. Imasogie Esq.Founder & Chairman · born 1962
- Dr. Oludare OdumosuMD, Global CEO & Director
- Mr. Greg BlakeExecutive Director
- Mr. Timothy Ryan SlateCompany Secretary & Non-Executive Director
- Mr. Rahul GanesanVice President of Finance & Accounting
- Dr. Patty WasherClinical Trial Consultant